HIV感染者全球CVD预防队列中CVD事件风险影响因素
在REPRIEVE全球队列7769例HIV感染者中,分析首次MACE及其亚组分的基线风险因素。调整他汀效应后,年龄较大、黑种人种族、早发CVD家族史、当前吸烟、高血压、较低HDL胆固醇、HIV-1 RNA≥LLQ及特定ART类别组合与首次MACE风险升高相关;女性性别未见保护作用。
要点
- 年龄50-59岁和≥60岁较40-49岁首次MACE风险更高。
- 当前吸烟、高血压、早发CVD家族史与首次MACE风险升高相关。
- 女性性别未见明显保护作用。
核心结论
- 在REPRIEVE队列HIV感染者中,部分可改变风险因素在考虑他汀效应后仍与首次MACE相关,女性性别未见保护作用。
研究设计与样本
- REPRIEVE全球队列研究,纳入7769例HIV感染者,中位年龄50岁,31%为女性。
主要发现
- 首次MACE风险:50-59岁 vs 40-49岁 HR 2.06(95%CI 1.54-2.76),≥60岁 vs 40-49岁 HR 2.53(95%CI 1.60-4.01)。
- 黑种人/非裔美国人种族(高收入国家内 vs 白种人)HR 1.65(95%CI 1.19-2.27),早发CVD家族史 HR 1.53(95%CI 1.16-2.03)。
- 当前吸烟 HR 2.27(95%CI 1.65-3.13),高血压 HR 1.77(95%CI 1.36-2.30),较低HDL胆固醇 HR 1.21(95%CI 1.10-1.34)。
- HIV-1 RNA≥LLQ HR 1.40(95%CI 1.0-1.97),特定ART类别组合 HR 1.53(95%CI 1.01-2.31)。
- 高收入国家个体较其他地区(除南亚外)首次MACE风险更高;硬MACE、MI和卒中的建模结果对多数变量相似。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persons with HIV face increased risks of major adverse cardiovascular events (MACE), partially mitigated by statin therapy. METHODS: We characterized factors associated with MACE and MACE subcomponents among PWH enrolled in REPRIEVE, globally. Our primary outcome measure was time-to-first primary MACE. Secondary outcome measures included time-to-first (1) hard MACE (cardiovascular disease [CVD] death, myocardial infarction [MI], or stroke), (2) MI, or (3) stroke. For each outcome, Cox proportional hazards models were used to estimate the hazard of baseline risk factors. RESULTS: Among participants (N = 7769), median age was 50 (Q1, Q3: 45, 55) years, and 31% were female. In fully adjusted models, risk of first MACE was higher for older individuals (50-59 and ≥60 vs 40-49 years; HR [95% CI]: 2.06 [1.54-2.76] and 2.53 [1.60-4.01]) and for those with Black/African-American race (vs White race, within HICs; HR: 1.65; 1.19-2.27), family history of premature CVD (HR: 1.53; 1.16-2.03), current cigarette smoking (HR: 2.27; 1.65-3.13), hypertension (HR: 1.77; 1.36-2.30), lower HDL cholesterol (HR: 1.21; 1.10-1.34), HIV-1 RNA ≥lower limit of quantification (LLQ) (HR: 1.40; 1.0-1.97), and a select antiretroviral therapy class combination (HR: 1.53; 1.01-2.31). Individuals from HICs had a higher risk of first MACE versus those from other regions, except South Asia. There was no apparent protective effect of female sex. Modeling for hard MACE, MI, and stroke yielded similar results for most variables. CONCLUSIONS: Among PWH in REPRIEVE, select modifiable risk factors were associated with first MACE after accounting for statin effects. Female sex was not protective. CLINICAL TRIALS REGISTRATION: NCT02344290 (ClinicalTrials.gov; date of initial registration: 22 January 2015).
引用
- Grinspoon SK, Watanabe M, Ribaudo HJ, et al. Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With HIV. Clin Infect Dis. 2026. PMID: 40281648. doi:10.1093/cid/ciaf210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。